US CAN STARTUP Invests in Rapidly Growing North American Startups, Including Kalino Bio
Kalino Bio did not arrive with a deck full of hope and buzzwords. It arrived with science, timing, and a sharp read on a problem the animal health industry has normalized for decades because it felt unavoidable. Founded in Vancouver in 2024, Kalino Bio is taking a hard look at one of the most common procedures in veterinary medicine and asking a question that makes people shift in their seats. If biology already offers better tools, why are we still cutting?
Dr. Shuai Sherry Zhao did not stumble into this lane. She built toward it. PhD in Chemistry from the University of British Columbia. BSc with distinction from Peking University. Early career reps at Genentech working on biologics characterization, followed by a decade at Mitacs scaling industry academic partnerships and helping secure a $50M government contract. That is not career variety. That is systems thinking. When Dr. Shuai Sherry Zhao stepped away in Sept 2024 and launched Strillence Strategic, the gaps in veterinary medicine did not whisper. They were obvious to anyone paying attention.
Kalino Bio is developing non surgical immunocontraceptive biologics for dogs and cats. Periodic injectable treatments designed to replace spaying and neutering. No anesthesia. No operating rooms. No recovery cycles that stress animals and strain clinics. The platform uses immunocontraception to induce temporary infertility by activating the immune system itself. GnRH based mechanisms. Peer reviewed biology. A category that has lived in research papers and wildlife programs but never fully crossed into companion animal care.
The market dynamics are not subtle. Global pet healthcare hit 65.9B in 2025. Spay and neuter alone sits at 2.7B and growing. Non surgical pet contraception is under 400M today but projected to nearly double. That delta is not academic. Shelters are capacity constrained. Clinics are overloaded. Owners face $200 to $600 procedures. Injection based solutions scale in ways surgery never will.
Kalino Bio raised over $1M in its founding round announced Oct 19, 2024, backed by veterinary KOLs and animal health angels who understood the signal. In Dec 2025, US CAN STARTUP came in with strategic capital and cross border leverage. Shun Ma backs endurance, not hype. Vancouver to Silicon Valley. Capital plus infrastructure plus patience.
This is still R&D. Preclinical validation. Regulatory paths through Health Canada and eventually the USDA. No shortcuts. No inflated claims. Just a company betting that humane, scalable biology will outlast invasive tradition. Kalino Bio is not trying to be loud. It is building toward inevitable.